You are here

Study: Substituting Methadone for Opioids Could Save Billions

Researchers find opioid-agonist treatment saves lives and money compared with detox

Policymakers and insurers have been pushing people addicted to opioids into abstinence-based detox programs, but a new study concludes that methadone and similar drug-maintenance treatments save lives and money, Reuters reports.

If the nearly 47,000 Californians who began treatment for opioid-use disorder in 2014 had received immediate access to methadone or another opioid-agonist treatment—instead of first being forced to completely withdraw from opioids—the health care and criminal-justice systems would have saved $3.8 billion, researchers estimate. In addition, 1,262 lives would have been spared, lead researcher Emanuel Krebs, a health economist at the British Columbia Center for Excellence in HIV/AIDS in Vancouver, British Columbia, told Reuters.

“If you offer opioid-agonist treatment from the outset, people live longer, and they incur lower costs on society,” added senior author Bohdan Nosyk, a health economist and professor at Simon Fraser University in Vancouver, British Columbia. “People may not want to stay in treatment, but it’s their best chance of staying alive,” he said in a Reuters interview.

Methadone and buprenorphine, opioid agonists, bind to the brain’s opioid receptors; the correct dose will eliminate withdrawal symptoms and cravings. International addiction experts consider initial opioid-agonist treatment (OAT), with no duration restrictions, the evidence-based standard of care for opioid-use disorder, the authors wrote online in the Annals of Internal Medicine.

But in California, where more people have been diagnosed with opioid disorder than in any other U.S. state, publicly funded treatment programs require patients to “fail”—twice—at a three-week course of medically supervised withdrawal before they become eligible for OAT.

“My belief is that California’s persisted with this medically managed withdrawal because they think they’re saving themselves money,” Nosyk said in the interview. “You’re paying more than that in the criminal-justice sector, in the health care section in the long run.”

Using state data, Nosyk, Krebs, and colleagues created a computer model to examine the impact immediate access to OAT would have had on Californians treated for opioid-use disorder in 2014. It would have saved as much as $850 million over five years, not including savings to the criminal-justice system, and more than $2 billion, including the cost of arrests and prosecutions, the study found.

Over 10 years, the total savings would rise to $2.87 billion, the model showed.

“We have to prevent new cases of addiction,” said Dr. Andrew Kolodny, co-director of opioid policy research at Brandeis University’s Heller School for Social Policy and Management in Boston. “But for the millions who are addicted, the study authors nailed it—the effective treatment, the opioid-agonist treatment, needs to be very easy to access.”

“It’s very hard to recover with an abstinence-based approach. Most people can’t do it, yet that’s been the first-line treatment. That’s why we’re failing,” he said in a phone interview with Reuters.

Opioids killed more than 33,000 people in the U.S. in 2015, according to the Centers for Disease Control and Prevention. Prescription painkillers are fueling the epidemic.

“If we want to see overdose deaths come down, we need to make sure people who have opioid addiction are able to access effective treatment more easily than they can access heroin, fentanyl, or pain pills,” said Kolodny, who was not involved with the study.

An editorial accompanying the study says it adds to decades of data on the efficacy of opioid agonists and should lead policymakers to spend fewer health care resources on medically supervised withdrawal and more on opioid-agonist treatment.

The editorial writers, Dr. Jeanette Tetrault and Dr. David Fiellin of Yale University School of Medicine in New Haven, Connecticut, likened treating opioid disorder with medically assisted withdrawal to treating diabetic ketoacidosis, a life-threatening complication of diabetes, without addressing diabetes.

“Among experts in the field of addiction, we already know that detox doesn’t work, that they’re going to relapse and when they relapse, they’re going to be at great risk for an overdose, that they’ll be at great risk for hepatitis,” Kolodny said. “Opioid addiction is a life-threatening illness.”

Source: Reuters; November 20, 2017.

More Headlines

Manufacturer used FDA’s 505(b)(2) abbreviated approval pathway
This is the first drug for patients with eosinophilic granulomatosis with polyangiitis
Industry will provide funding for programs in partnership with Addiction Policy Forum
Platform offers advanced technology to treat symptoms of Parkinson’s disease
Four in 10 remain in complete remission, updated data show
Patients with high PD-L1 level show benefit in first-line treatment
Pfizer launches generic to counteract Teva’s version
Tecentriq was combined with Avastin and chemotherapy as initial treatment